These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 23871153

  • 1. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, Hanna NN, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE.
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [Abstract] [Full Text] [Related]

  • 2. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
    Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, Chapoval A, Schulze DH, Tian G, Strome SE.
    Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
    [Abstract] [Full Text] [Related]

  • 3. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.
    Clin Cancer Res; 2013 Mar 01; 19(5):1126-38. PubMed ID: 23209031
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
    Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X.
    Hum Antibodies; 2010 Mar 01; 19(4):89-99. PubMed ID: 21178280
    [Abstract] [Full Text] [Related]

  • 6. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
    Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H, Morreau H, van der Burg SH, Guchelaar HJ, van Hall T.
    Clin Cancer Res; 2011 Sep 01; 17(17):5668-73. PubMed ID: 21788356
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies.
    Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, Peipp M, Valerius T.
    J Immunol; 2012 Dec 01; 189(11):5230-9. PubMed ID: 23100515
    [Abstract] [Full Text] [Related]

  • 9. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G.
    Cancer Res; 2004 Jul 01; 64(13):4664-9. PubMed ID: 15231679
    [Abstract] [Full Text] [Related]

  • 10. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S, Steinbacher J, Schmiedel BJ, Kousis PC, Steinle A, Jung G, Grosse-Hovest L, Salih HR.
    J Immunol; 2014 Oct 15; 193(8):4261-72. PubMed ID: 25217158
    [Abstract] [Full Text] [Related]

  • 11. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
    Li G, Zhang L, Chen E, Wang J, Jiang X, Chen JH, Wickman G, Amundson K, Bergqvist S, Zobel J, Buckman D, Baxi SM, Bender SL, Casperson GF, Hu-Lowe DD.
    Cancer Res; 2010 Dec 15; 70(24):10243-54. PubMed ID: 21159645
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
    Oboshi W, Watanabe T, Matsuyama Y, Kobara A, Yukimasa N, Ueno I, Aki K, Tada T, Hosoi E.
    Hum Immunol; 2016 Feb 15; 77(2):165-71. PubMed ID: 26582002
    [Abstract] [Full Text] [Related]

  • 14. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
    Hsieh YT, Aggarwal P, Cirelli D, Gu L, Surowy T, Mozier NM.
    J Immunol Methods; 2017 Feb 15; 441():56-66. PubMed ID: 27939300
    [Abstract] [Full Text] [Related]

  • 15. FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.
    Talathi SP, Shaikh NN, Pandey SS, Saxena VA, Mamulwar MS, Thakar MR.
    BMC Infect Dis; 2019 Dec 16; 19(1):1053. PubMed ID: 31842762
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
    Levy EM, Sycz G, Arriaga JM, Barrio MM, von Euw EM, Morales SB, González M, Mordoh J, Bianchini M.
    Innate Immun; 2009 Apr 16; 15(2):91-100. PubMed ID: 19318419
    [Abstract] [Full Text] [Related]

  • 18. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F, Surowy T.
    J Immunol Methods; 2014 Dec 01; 414():69-81. PubMed ID: 25086226
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.